1 / 17

Clinical & Translational Science: Individualizing Cancer Immunotherapy

Clinical & Translational Science: Individualizing Cancer Immunotherapy. Scott A. Waldman, MD, PhD, FCP Thomas Jefferson University. Clinical & Translational Science: Individualizing Cancer Immunotherapy. Scott A. Waldman, MD, PhD, FCP

dawson
Download Presentation

Clinical & Translational Science: Individualizing Cancer Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical & Translational Science:Individualizing Cancer Immunotherapy Scott A. Waldman, MD, PhD, FCP Thomas Jefferson University

  2. Clinical & Translational Science:Individualizing Cancer Immunotherapy Scott A. Waldman, MD, PhD, FCP Director, Delaware Valley Institute for Clinical and Translational Science Chair, Department of Pharmacology and Experimental Therapeutics Director, GI Malignancies Program, Kimmel Cancer Center Thomas Jefferson University Philadelphia, Pennsylvania

  3. Disclosures • I am the Chair of the Scientific Advisory Board of Targeted Diagnostics & Therapeutics, Inc. (TDT; uncompensated) • TDT provides research support to my laboratory • TDT licenses patents which are the subject of this presentation • This technology has been sublicensed to DiagnoCure, which does not provide support for this work • I am entitled to a share of royalties collected by Thomas Jefferson University upon the sale of products resulting from patents on which I am an inventor

  4. Delaware Health Sciences Alliance

  5. Translational Investigators Delaware Valley Institute for Clinical and Translational Science (DVICTS)

  6. Colorectal Cancer and Women

  7. Stage, Prognosis and Prediction Stage Stage I Stage II Stage III Stage IV Recurrence (%) % of cases at presentation 14 28 37 21 20 40 % 5 year survival Caucasian 89 64 38 3 African American

  8. The One-Two Punch:Finding and Eradicating Occult Metastases

  9. N T F Y C C E L C C N P A C A G C Y Guanylyl Cyclase C (GCC) as a Marker and Target in Colon Cancer

  10. The First Punch:Identifying Patients with Occult Metastases

  11. Identifying Patients With Occult Metastases Using Molecular Detection Low Risk (<5%) High Risk (>80%) Hazard Ratio=65

  12. The Second Punch:Eliminating Occult Metastases

  13. Novel Vaccine Approaches to Colon Cancer: Cancer Mucosal Antigens 3 2 4 Effector T cells CRC Metastases Tcell APC X 5 1 Cancer Mucosa Antigens

  14. 100 Control GCC 80 p<0.001 60 Percent Survival 40 20 0 20 30 40 Days GCC Vaccine Protects Against Metastatic Colon Cancer in Mice 400 300 Tumor Number 200 100 *** 0 Control GCC Immunization

  15. 100 Control GCC 80 p<0.001 60 Percent Survival 40 20 0 20 30 40 Days Individualizing Cancer Immunotherapy

  16. Acknowledgements Thomas Jefferson Universityand Kimmel Cancer Center • Pharmacology • Stephanie Schulz • Peng Li • Janis Haaf • Chris Bonaccorso • Egeria Lin • Ahmara Gibbon • Michael Valentino • David Zuzga • Adam Snook • Alex Meija • Medical Oncology • Edith Mitchell • Pathology • Juan Palazzo • Biostatistics • Terry Hyslop • Surgery • Scott Goldstein • Gerald Isenberg Christiana Care • Bruce Boman • Nicholas Petrelli Funding • NIH • PA Department of Health • TDT, Inc.

More Related